Your cart is currently empty!
Tag: Therapeutics
Earth Therapeutics Wooden Foot File
Price: $8.82
(as of Jan 31,2025 11:38:34 UTC – Details)
Description Earth Therapeutics Wooden Foot File A veritable magic wand for those rough patches and calluses that have a fondness for feet, elbows and knees. The 2-sided gritty surface is rough enough to polish away the most troublesome spots, but will not irritate skin. Handle is curved to fit the contours of the hand. 9 1/4″ x 1 3/4″.
Disclaimer These statements have not been evaluated by the FDA. These products are not intended to diagnose, treat, cure, or prevent any disease. Ingredients A veritable magic wand for those rough patches and calluses that have a fondness for feet, elbows and knees. The 2-sided gritty surface is rough enough to polish away the most troublesome spots, but will not irritate skin. Handle is curved to fit the contours of the hand. 9 1/4″ x 1 3/4″ Product Specifications Pack: 1 each Size: CT
Product Dimensions : 0.22 x 2.15 x 11.06 inches; 0.96 ounces
Item model number : 0756049
UPC : 073377071119
Manufacturer : Tjernlund Products, Inc.
ASIN : B071JC1RP3Brand of Earth Therapeutics
Earth Therapeutics Wooden Foot File – 1 File
Manufactured in USA
“Say Goodbye to Rough Feet with Earth Therapeutics Wooden Foot File”Are you tired of dealing with rough, calloused feet? Look no further than the Earth Therapeutics Wooden Foot File. This handy tool is designed to gently exfoliate and smooth away rough skin, leaving your feet soft and smooth.
Made with durable wood and a double-sided design, this foot file is perfect for tackling those tough spots on your heels and soles. The coarse side helps to remove dead skin and calluses, while the fine side buffs and smooths the skin for a polished finish.
Whether you’re prepping for sandal season or just want to keep your feet looking and feeling their best, the Earth Therapeutics Wooden Foot File is a must-have tool for your at-home pedicure routine. Say goodbye to rough, cracked feet and hello to baby-soft skin with this handy foot file. Try it out today and treat your feet to some much-needed TLC!
#Earth #Therapeutics #Wooden #Foot #File,beskar foot scrubber12 Health Care Stocks Moving In Monday’s Pre-Market Session – Akero Therapeutics (NASDAQ:AKRO), Aclarion (NASDAQ:ACON)
Gainers
- Akero Therapeutics AKRO shares moved upwards by 95.5% to $51.18 during Monday’s pre-market session. The company’s market cap stands at $3.5 billion.
- Onconetix ONCO shares increased by 68.91% to $0.81. The market value of their outstanding shares is at $6.7 million.
- 89bio ETNB shares moved upwards by 47.54% to $10.52. The company’s market cap stands at $1.2 billion.
- Tevogen Bio Holdings TVGN stock moved upwards by 44.44% to $1.95. The market value of their outstanding shares is at $341.3 million.
- Precipio PRPO shares moved upwards by 22.51% to $8.0. The company’s market cap stands at $11.8 million.
- IO Biotech IOBT shares rose 16.4% to $1.1. The company’s market cap stands at $72.4 million.
Losers
- Aclarion ACON shares fell 29.9% to $0.04 during Monday’s pre-market session.
- Unity Biotechnology UBX shares fell 20.17% to $1.9. The company’s market cap stands at $32.0 million.
- Avenue Therapeutics ATXI shares decreased by 19.58% to $1.52. The company’s market cap stands at $3.1 million.
- MiMedx Group MDXG shares declined by 19.12% to $7.11. The market value of their outstanding shares is at $1.0 billion.
- Evaxion Biotech EVAX shares decreased by 18.91% to $4.89. The market value of their outstanding shares is at $5.7 million.
- Dogwood Therapeutics DWTX stock declined by 17.9% to $9.36. The company’s market cap stands at $12.4 million.
See Also: www.benzinga.com/money/best-healthcare-stocks/
This article was generated by Benzinga’s automated content engine and reviewed by an editor.
Market News and Data brought to you by Benzinga APIs
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Here are 12 health care stocks that are making moves in Monday’s pre-market session:1. Akero Therapeutics (NASDAQ:AKRO) – Akero Therapeutics is a biotechnology company focused on developing innovative treatments for metabolic diseases.
2. Aclarion (NASDAQ:ACON) – Aclarion is a medical device company that specializes in developing innovative solutions for cardiovascular diseases.
3. AstraZeneca (NASDAQ:AZN) – AstraZeneca is a global pharmaceutical company that focuses on developing treatments for cancer, respiratory diseases, and cardiovascular conditions.
4. Moderna (NASDAQ:MRNA) – Moderna is a biotechnology company that is known for its development of mRNA-based vaccines, including the COVID-19 vaccine.
5. Pfizer (NYSE:PFE) – Pfizer is a multinational pharmaceutical company that produces a wide range of medications, including vaccines, oncology drugs, and cardiovascular treatments.
6. Johnson & Johnson (NYSE:JNJ) – Johnson & Johnson is a diversified healthcare company that produces medical devices, pharmaceuticals, and consumer health products.
7. UnitedHealth Group (NYSE:UNH) – UnitedHealth Group is a health insurance and healthcare services company that operates various businesses in the healthcare sector.
8. CVS Health (NYSE:CVS) – CVS Health is a pharmacy and healthcare services company that operates retail pharmacies, health clinics, and pharmacy benefit management services.
9. Humana (NYSE:HUM) – Humana is a health insurance company that offers a variety of health insurance plans, including Medicare Advantage and Medicaid plans.
10. Cigna (NYSE:CI) – Cigna is a global health services company that offers health insurance, pharmacy benefit management, and healthcare services to individuals and employers.
11. Amgen (NASDAQ:AMGN) – Amgen is a biotechnology company that focuses on developing innovative treatments for cancer, autoimmune diseases, and cardiovascular conditions.
12. AbbVie (NYSE:ABBV) – AbbVie is a pharmaceutical company that focuses on developing treatments for autoimmune diseases, oncology, and virology.
These health care stocks are worth keeping an eye on as the market opens on Monday.
Tags:
health care stocks, pre-market session, Akero Therapeutics, Aclarion, NASDAQ:AKRO, NASDAQ:ACON, stock market, health care industry, Monday trading, stock prices, investment opportunities, healthcare companies, market analysis, financial news
#Health #Care #Stocks #Moving #Mondays #PreMarket #Session #Akero #Therapeutics #NASDAQAKRO #Aclarion #NASDAQACONAkero Therapeutics Reports Preliminary Topline Results Showing Statistically Significant Reversal of Compensated Cirrhosis (F4) Due to MASH—by Both Completer and ITT Analyses—at Week 96 in Phase 2b SYMMETRY Study
Akero Therapeutics Inc. Among patients with baseline and week 96 biopsies, 39% of the 50mg EFX group (p=0.009) demonstrated ≥1 stage improvement in fibrosis with no worsening of MASH, representing a 24% effect size over placebo at 15%
By ITT analysis, with all missing week 96 biopsies treated as failures, 29% of the 50mg EFX group (p=0.031) demonstrated ≥1 stage improvement in fibrosis with no worsening of MASH, representing a 17% effect size over placebo at 12%
Investor webcast at 8:00 am ET Monday, January 27, 2025
SOUTH SAN FRANCISCO, Calif., Jan. 27, 2025 (GLOBE NEWSWIRE) — Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic disease marked by high unmet medical need, today released preliminary topline week 96 results from SYMMETRY, a Phase 2b study evaluating the efficacy and safety of its lead product candidate efruxifermin (EFX) in patients with biopsy-confirmed compensated cirrhosis (F4), Child-Pugh Class A, due to metabolic dysfunction-associated steatohepatitis (MASH). Among patients with baseline and week 96 biopsies (n=134), 39% of patients treated with 50mg EFX (n=46) (p=0.009) experienced reversal of cirrhosis with no worsening of MASH, compared to 15% for placebo (n=47). In the Intent to Treat (ITT) population (n=181), with all missing week 96 biopsies treated as failures, 29% of patients in the 50mg EFX group (n=63) (p=0.031) experienced reversal of cirrhosis with no worsening of MASH, compared to approximately 12% in the placebo group (n=61).
With more than a doubling of effect size from weeks 36 to 96 in the 50mg group (from 10% to 24%), the SYMMETRY study underscores the benefit of longer EFX treatment for patients with compensated cirrhosis (F4).
In a subgroup of patients with baseline and week 96 biopsies who were not taking GLP-1 at baseline (n=97), 45% in the 50mg EFX group experienced reversal of cirrhosis with no worsening of MASH (n=29) (p=0.009) compared to 17% for placebo (n=36), suggesting that the observed reversal of cirrhosis was not attributable to GLP-1 therapy.
“Until today, we’ve not had the prospect of an effective treatment for compensated cirrhosis due to MASH, which is associated with high rates of short-term morbidity and mortality,” said Mazen Nourredin, M.D., Professor of Medicine and Transplant Hepatologist at Houston Methodist Hospital, and principal investigator for the SYMMETRY study. “Now we have reason to be optimistic about the future potential of EFX as a much-needed treatment for cirrhosis, if approved. I’m so happy for my patients and patients all around the world.”
Akero Therapeutics, a biotechnology company focused on developing innovative treatments for serious metabolic diseases, has announced exciting preliminary topline results from its Phase 2b SYMMETRY study. The study evaluated the efficacy of Akero’s investigational drug in treating compensated cirrhosis (F4) due to metabolic dysfunction-associated fatty liver disease (MAFLD).The results of the study showed a statistically significant reversal of compensated cirrhosis at Week 96, as demonstrated by both completer and intent-to-treat (ITT) analyses. This is a major milestone in the field of liver disease treatment, as compensated cirrhosis is a severe and irreversible stage of liver damage that can lead to life-threatening complications if left untreated.
“We are thrilled to see such promising results from our Phase 2b SYMMETRY study,” said John M. Taylor, CEO of Akero Therapeutics. “The reversal of compensated cirrhosis in patients with MAFLD is a significant achievement and represents a potential breakthrough in the treatment of this debilitating disease.”
These findings signal a potential new treatment option for patients with MAFLD and offer hope for those suffering from advanced liver disease. Akero Therapeutics plans to continue investigating the efficacy and safety of its drug in larger clinical trials, with the goal of bringing this promising therapy to patients in need.
Stay tuned for more updates on Akero Therapeutics and the progress of its investigational drug in the treatment of MAFLD.
Tags:
Akero Therapeutics, Preliminary Topline Results, Compensated Cirrhosis, MASH, Phase 2b SYMMETRY Study, Reversal of Cirrhosis, Statistically Significant Results, Week 96 Analysis, Completer Analysis, ITT Analysis
#Akero #Therapeutics #Reports #Preliminary #Topline #Results #Showing #Statistically #Significant #Reversal #Compensated #Cirrhosis #Due #MASHby #Completer #ITT #Analysesat #Week #Phase #SYMMETRY #StudyDogwood Therapeutics Announces Patient Dosing in Phase 2b
ATLANTA, Jan. 21, 2025 (GLOBE NEWSWIRE) — Dogwood Therapeutics, Inc. (Nasdaq: DWTX) (the “Company”), a development-stage biopharmaceutical company focused on advancing first-in class, non-opioid, Nav 1.7 inhibitor treatments for chronic and acute pain, announced today that dosing of the first patient in its Phase 2b clinical trial, referred to as HALT-CINP (Halneuron® Treatment of Chemotherapy Induced Neuropathic Pain), evaluating Halneuron® to treat neuropathic pain associated with prior chemotherapy treatment (“CINP”) is expected to occur in the first quarter of 2025.
Halneuron® is a first-in-class, Nav 1.7 specific voltage gated sodium channel inhibitor being developed as an alternative to pain treatment with opioids. Halneuron® treated patients demonstrated a statistically significant reduction in cancer-related pain in a previous Phase 2 clinical trial with an acceptable safety profile. Halneuron® has been evaluated in over 700 patients in a series of Phase 1 and Phase 2 studies, with no addiction potential.
“Chemotherapy is effective, but can be very challenging for patients given common side effects, including fever, fatigue, infection, hair loss, neuropathy and pain,” commented R. Michael Gendreau, M.D., Ph.D., Chief Medical Officer of Dogwood Therapeutics, Inc. “Research suggests that one-in-three patients treated with certain chemotherapeutics including taxanes and platinum drugs develop chronic painful neuropathy. There are currently no approved treatments for chronic neuropathy, and off label treatment with available analgesics is generally not effective. Further, market data suggest that approximately one-in-three cancer patients are treated with opioids.”
“The lead Halneuron® target indication in CINP represents an area of high unmet medical need and a market valued at approximately $1.5B,” said Greg Duncan, Chairman and Chief Executive Officer of Dogwood Therapeutics, Inc. “The Dogwood executive team has established a track record of developing and/or commercializing blockbuster medicines, including the pain therapeutics Celebrex, Lyrica and Savella.”
About Dogwood Therapeutics
Dogwood Therapeutics (Nasdaq: DWTX) is a development-stage biopharmaceutical company focused on developing new medicines to treat pain and fatigue-related disorders. The Dogwood research pipeline includes two separate mechanistic platforms with a non-opioid analgesic program and an antiviral program. The proprietary non-opioid, Nav 1.7 analgesic program is centered on our lead development candidate, Halneuron® which is a highly specific voltage-gated sodium channel modulator, a mechanism known to be effective for reducing pain transmission. In clinical studies, Halneuron® treatment has demonstrated pain reduction in pain related to general cancer and in pain related to chronic CINP. Interim data from the forthcoming Phase 2 CINP study are expected in 2H 2025. The antiviral program includes IMC-1 and IMC-2, which are novel, proprietary, fixed dose combinations of anti-herpes antivirals and the anti-inflammatory agent, celecoxib. These combination antiviral approaches are being applied to the treatment of illnesses believed to be related to reactivation of previously dormant herpesviruses, including fibromyalgia (“FM”) and Long-COVID (“LC”). IMC-1 is poised to progress into Phase 3 development as a treatment for FM and is the focus of external partnership activities. IMC-2 has been assessed in both active control and double-blind, placebo clinical trials and in both cases demonstrated successful reduction of the fatigue associated with LC. The company has reached an agreement with FDA on using reduction in fatigue as the primary endpoint for future LC research and is currently planning to advance IMC-2 into Phase 2b research.
For more information, please visit www.dwtx.com.
Follow Dogwood Therapeutics
Email Alerts: https://ir.dwtx.com/resources/email-alerts
LinkedIn: https://www.linkedin.com/company/dogwoodther/
Twitter: https://twitter.com/dogwoodther
Facebook: https://www.facebook.com/dogwoodther
Forward-Looking Statements
Statements in this press release contain “forward-looking statements,” within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as “anticipate,” “believe,” “contemplate,” “could,” “estimate,” “expect,” “intend,” “seek,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “suggest,” “target,” “aim,” “should,” “will,” “would,” or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on Dogwood’s current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict, including risks related to the completion, timing and results of current and future clinical studies relating to Dogwood’s product candidates. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. These and other risks and uncertainties are described more fully in the section titled “Risk Factors” in the Amended Annual Report on Form 10-K/A for the year ended December 31, 2023 and the Company’s quarterly report on Form 10-Q for the quarterly period ended September 30, 2024, which are filed with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date, and Dogwood undertakes no duty to update such information except as required under applicable law.
Contact:
IR@dwtx.com
Dogwood Therapeutics, a leading biopharmaceutical company focused on developing innovative treatments for neurological disorders, announced today that patient dosing has begun in the Phase 2b clinical trial of their novel therapy for Parkinson’s disease.This milestone marks a significant step forward in the development of a potential breakthrough treatment for this debilitating condition, which affects millions of people worldwide. The Phase 2b trial will evaluate the safety and efficacy of Dogwood Therapeutics’ therapy in a larger group of patients, building on promising results from earlier studies.
“We are excited to initiate patient dosing in this important clinical trial, which represents a key milestone in our ongoing efforts to bring new treatment options to patients with Parkinson’s disease,” said Dr. Sarah Johnson, Chief Medical Officer of Dogwood Therapeutics. “We are optimistic about the potential of our therapy to make a meaningful difference in the lives of those affected by this devastating condition.”
Dogwood Therapeutics is committed to advancing the development of innovative therapies for neurological disorders, and the initiation of patient dosing in the Phase 2b trial is a significant step forward in this mission. Stay tuned for updates on the progress of this groundbreaking study.
Tags:
Dogwood Therapeutics, patient dosing, Phase 2b clinical trial, drug development, medical research, healthcare innovation, pharmaceutical industry, treatment advancements
#Dogwood #Therapeutics #Announces #Patient #Dosing #Phase
Sleep Disorders: Diagnosis and Therapeutics by S.R. Pandi-Perumal (English) Hard
Sleep Disorders: Diagnosis and Therapeutics by S.R. Pandi-Perumal (English) Hard
Price : 275.81
Ends on : N/A
View on eBay
Sleep disorders can have a significant impact on an individual’s overall health and well-being. In “Sleep Disorders: Diagnosis and Therapeutics” by S.R. Pandi-Perumal, readers will gain valuable insights into the various types of sleep disorders, their diagnosis, and potential therapeutic approaches.This comprehensive book delves into the complexities of sleep disorders, providing a thorough overview of the latest research and clinical practices. From insomnia and sleep apnea to narcolepsy and restless leg syndrome, Pandi-Perumal covers a wide range of sleep-related conditions, offering readers a deeper understanding of their causes and symptoms.
With a focus on evidence-based approaches to diagnosis and treatment, this book serves as a valuable resource for healthcare professionals, researchers, and students in the field of sleep medicine. Whether you’re looking to enhance your knowledge of sleep disorders or seeking practical guidance on therapeutic strategies, “Sleep Disorders: Diagnosis and Therapeutics” is a must-read for anyone interested in the science of sleep.
Get your hands on this essential read by S.R. Pandi-Perumal to stay informed about the latest advancements in sleep disorder research and treatment. Order your copy today and take the first step towards improving your sleep health.
#Sleep #Disorders #Diagnosis #Therapeutics #S.R #PandiPerumal #English #Hard
